Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
An October BMJ paper that does not appear to be being properly considered or reported to balance the euphoria of vaccine reporting.
To quote:
But what will it mean exactly when a vaccine is declared “effective”? To the public this seems fairly obvious. “The primary goal of a covid-19 vaccine is to keep people from getting very sick and dying,” a National Public Radio broadcast said bluntly.
Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine in Houston, said, “Ideally, you want an antiviral vaccine to do two things . . . first, reduce the likelihood you will get severely ill and go to the hospital, and two, prevent infection and therefore interrupt disease transmission.”
Yet the current phase III trials are not actually set up to prove either (table 1). None of the trials currently under way are designed to detect a reduction in any serious outcome such as hospital admissions, use of intensive care, or deaths. Nor are the vaccines being studied to determine whether they can interrupt transmission of the virus.
https://www.bmj.com/content/371/bmj.m4037
A LTH of ODX
An October BMJ paper that does not appear to be being properly considered or reported to balance the euphoria of vaccine reporting.
To quote:
But what will it mean exactly when a vaccine is declared “effective”? To the public this seems fairly obvious. “The primary goal of a covid-19 vaccine is to keep people from getting very sick and dying,” a National Public Radio broadcast said bluntly.
Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine in Houston, said, “Ideally, you want an antiviral vaccine to do two things . . . first, reduce the likelihood you will get severely ill and go to the hospital, and two, prevent infection and therefore interrupt disease transmission.”
Yet the current phase III trials are not actually set up to prove either (table 1). None of the trials currently under way are designed to detect a reduction in any serious outcome such as hospital admissions, use of intensive care, or deaths. Nor are the vaccines being studied to determine whether they can interrupt transmission of the virus.
https://www.bmj.com/content/371/bmj.m4037
A LTH of GDR
An October BMJ paper that does not appear to be being properly considered or reported to balance the euphoria of vaccine reporting.
To quote:
But what will it mean exactly when a vaccine is declared “effective”? To the public this seems fairly obvious. “The primary goal of a covid-19 vaccine is to keep people from getting very sick and dying,” a National Public Radio broadcast said bluntly.
Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine in Houston, said, “Ideally, you want an antiviral vaccine to do two things . . . first, reduce the likelihood you will get severely ill and go to the hospital, and two, prevent infection and therefore interrupt disease transmission.”
Yet the current phase III trials are not actually set up to prove either (table 1). None of the trials currently under way are designed to detect a reduction in any serious outcome such as hospital admissions, use of intensive care, or deaths. Nor are the vaccines being studied to determine whether they can interrupt transmission of the virus.
https://www.bmj.com/content/371/bmj.m4037
A LTH of Avacta
Try these for size too
https://www.huffingtonpost.co.uk/entry/the-drug-trial-bbc-examines-what-went-wrong-in-the-infamous-elephant-men-case_uk
https://listverse.com/2017/06/19/top-10-clinical-trials-that-went-horribly-wrong/
Take a look at this company offering. In the same fin tech bracket as Syme? Would appear to me to reinforce the philosophy underpinning Syme’s proposition.
https://fabriik.com/
I could be talking sh**e of course!
Post Covid long term lung damage is going to need a treatment. Co crystal technology has been demonstrated to improve the efficacy of existing drugs in this area. Ergo there is a real problem due to Covid, and a potential real solution. Lets give those in NFX putting their livelihoods and reputations on the line the benefit of the doubt.
See these articles for more info.
https://www.healthline.com/health-news/lifelong-lung-damage-the-serious-covid-19-complication-that-can-hit-people-in-their-20s
https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/coronavirus-long-term-effects/art-20490351
https://www.bmj.com/content/370/bmj.m3001
So I might be wearing rose tinted spectacles , with 350k shares at 11p since last year, pre-Covid, but I really do believe in the tech and its possibilities, for richer for poorer etc.
The allocation is based on your holding as at cob 15 October (so my platform informs me). Whatever you do with your holding after that cut off is not material in the 1 for 37 allocation. Of course you can confirm this for yourself.
See this article, near the bottom.
https://unherd.com/2020/10/is-moonshot-testing-a-waste-of-money/
Interesting information on Moonshot company
https://unherd.com/2020/10/is-moonshot-testing-a-waste-of-money/
Having not heard of OO until I agreed my Hvivo shares be converted, I then sat at 6p with 66660 shares with a view to break even in OO of ca 32p. I thought all I have to do is hold and pray and wondered if ever that would come to pass. The more I read and saw of CF and what he was about with OO the more confident I became. So I sold some other dogs and averaged down to 21p, and sat tight. As of today I am in profit and looking forward to the next few months, holding tight, looking forward to the ride. Seriously hoping CF and OO can really set light to my Xmas pudding, or even potentially blow it to smithereens!
This is a test to show you have had Covid, not got it! Its needed to get a handle on population penetration ("herd immunity"), as well as in the future working out of targets for vaccine distribution.
Another extract re wastewater:
Scarpino told me that overdispersion also enhances the utility of other aggregate methods, such as wastewater testing, especially in congregate settings like dorms or nursing homes, allowing us to detect clusters without testing everyone. Wastewater testing also has low sensitivity; it may miss positives if too few people are infected, but that’s fine for population-screening purposes. If the wastewater testing is signaling that there are likely no infections, we do not need to test everyone to find every last potential case. However, the moment we see signs of a cluster, we can rapidly isolate everyone, again while awaiting further individualized testing via PCR tests, depending on the situation.
Another extract:
In an overdispersed regime, identifying transmission events (someone infected someone else) is more important than identifying infected individuals. Consider an infected person and their 20 forward contacts—people they met since they got infected. Let’s say we test 10 of them with a cheap, rapid test and get our results back in an hour or two. This isn’t a great way to determine exactly who is sick out of that 10, because our test will miss some positives, but that’s fine for our purposes. If everyone is negative, we can act as if nobody is infected, because the test is pretty good at finding negatives. However, the moment we find a few transmissions, we know we may have a super-spreader event, and we can tell all 20 people to assume they are positive and to self-isolate—if there are one or two transmissions, there are likely more, exactly because of the clustering behavior. Depending on age and other factors, we can test those people individually using PCR tests, which can pinpoint who is infected, or ask them all to wait it out.
An extract from the link below. Covid infection event cluster identification is more important than identifying individual agency.
“Meanwhile, researchers have shown that rapid tests that are very accurate for identifying people who do not have the disease, but not as good at identifying infected individuals, can help us contain this pandemic. As Dylan Morris, a doctoral candidate in ecology and evolutionary biology at Princeton, told me, cheap, low-sensitivity tests can help mitigate a pandemic even if it is not overdispersed, but they are particularly valuable for cluster identification during an overdispersed one. This is especially helpful because some of these tests can be administered via saliva and other less-invasive methods, and be distributed outside medical facilities.”
https://www.theatlantic.com/health/archive/2020/09/k-overlooked-variable-driving-pandemic/616548/
See this paper
https://dash.harvard.edu/bitstream/handle/1/37363184/Transmission%20Tracing%20-%20Kennedy-Shaffer%20Baym%20Hanage.pdf?sequence=1&isAllowed=y
Why fast testing is a game changer for getting on top of the pandemic. Needs high volume low cost moderate sensitivity tests.
Got f*** all to do with the Daily Mail as a vehicle! Don’t shoot the messenger! Look at the substance of the story in terms of understanding big government linking with big Pharma and a centralised PHE & MHRA, and associated groupthink, so neutralising the potential impact of innovative, disruptive smaller companies with novel technologies.
Declaration of an interest? Where and when?
https://www.dailymail.co.uk/news/article-8772503/Sir-Patrick-Valance-wealthiest-mandarin-Whitehall-took-600-000-pay-cut-government.html
IMHO this is AZ being opportunistic in promoting his business model to a class of potential client unlikely to have yet been reached. Getting it out there in this way using a social media force multiplier is a stroke of pre-emptive genius. It publicly challenges head on the traditional analogue fund raising model to consider something unique and new, of the C21st, underpinned by a blockchain supported service. May even have the banks and the sovereign wealth funds reaching for the phone in the morning!